Myositis complicating viridans streptococcal sepsis in childhood leukemia

Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatric Blood & Cancer (Impact Factor: 2.39). 03/2005; 44(3):277-9. DOI: 10.1002/pbc.20225
Source: PubMed


Hematogenous focal infections are a rare complication of bacteremia or sepsis caused by viridans-group streptococci. We describe two patients with acute leukemia who developed myositis during alpha-hemolytic streptococcal bacteremia. Children complaining of severe muscle pain associated with viridans streptococcal infections should be carefully evaluated for the presence of focal pyogenic complications and rhabdomyolysis. The severity of infectious myositis is highly variable, depending on the etiologic organism and host immunity, making individualized treatment the most effective approach.

Download full-text


Available from: Scott C Howard, Nov 17, 2014
23 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Viridans group streptococci (VGS) are major pathogens among children with cancer or receiving hematopoietic stem cell transplantation and are associated with considerable morbidity and mortality rates. The incidence and severity of VGS infections have increased during the past 15 years and account for as many as one third of all bacteremic episodes. Risk factors include severe neutropenia, mucositis, gastrointestinal toxicity, pneumonia, younger age, and high-intensity chemotherapy (especially cytosine arabinoside). VGS no longer can be assumed to be susceptible to penicillin because as many as 37 percent of VGS isolates harbor high levels of resistance (minimum inhibitory concentration >4 microg/mL). Furthermore, resistance to multiple classes of antibiotics, including beta-lactams and fluoroquinolones, has now been documented and is increasing in prevalence. In this article, we present a brief overview of VGS, describe the clinical spectrum of VGS-related diseases in children with cancer, and review the recent data regarding the incidence, clinical significance, and management of emerging antibiotic resistance among VGS.
    Seminars in Pediatric Infections Diseases 08/2006; 17(3):153-60. DOI:10.1053/j.spid.2006.06.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infection with viridans group streptococci (VGS) causes morbidity and mortality in children with cancer. Incidence of these infections has increased over time. Neutropenic patients with acute myeloid leukemia and those receiving high-dose cytarabine or undergoing stem cell transplantation are at highest risk. One-third of infected patients develop a shock syndrome despite prompt antibiotic therapy. Host defense mechanisms contribute substantially to colonization and tissue damage, but the origin of the shock syndrome is not well understood. VGS infection may be accompanied by neurological complications, myocarditis, and acute respiratory distress syndrome. Routine systemic antimicrobial prophylaxis against VGS infection has not been proven effective. Current recommendations include appropriate antibiotic therapy and intensive supportive care.
    Pediatric Blood & Cancer 11/2007; 49(6):774-80. DOI:10.1002/pbc.21250 · 2.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rhabdomyolysis with myoglobinuria is an uncommon complication of bacterial sepsis. The authors describe three pediatric acute lymphoblastic leukemia patients who developed rhabdomyolysis during a neutropenic sepsis episode due to Escherichia coli. All of the patients needed hemodynamic supportive treatment because of septic shock. Broad-spectrum antibiotics, alkalinization, and intravenous fluid therapy was given. One patient with renal insufficiency died, despite aggressive treatment. Muscle pain and dark urine color should alert physicians to the possibility of rhabdomyolysis in immunocompromised patients with sepsis. Early and appropriate treatment is critical in these patients to prevent renal failure and shock, and for a better outcome.
    Pediatric Hematology and Oncology 04/2009; 26(2):57-62. DOI:10.1080/08880010802434990 · 1.10 Impact Factor